FLT-3 aberrations in acute promyelocytic leukaemia:: clinicopathological associations and prognostic impact

被引:40
作者
Au, WY
Fung, A
Chim, CS
Lie, AK
Liang, R
Ma, ESK
Chan, CH
Wong, KF
Kwong, YL
机构
[1] Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[4] Queen Elizabeth Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
FLT-3; aberrations; acute promyelocytic leukaemia;
D O I
10.1111/j.1365-2141.2004.04935.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FLT-3 aberrations that occur as an internal tandem duplication (ITD) or a mutation at the activation-loop position 835, D835, are common in acute promyelocytic leukaemia (APL). We investigated the clinicopathological associations and prognostic impact of FLT-3 aberrations in a cohort of APL patients. FLT-3 exons 11 and 12 were amplified by polymerase chain reaction (PCR), and the ITD was recognized as an increase in the size of the PCR product. FLT-3 exon 17 was amplified, and D835 mutation was identified by loss of an EcoRV site, followed by DNA sequencing. Of 82 patients studied, FLT-3 aberrations were detected in 35 cases (43%) at diagnosis (ITD: 16; D835 mutation: 18; ITD + D835 mutation: 1). FLT-3 ITD, but not D835 mutations, was significantly associated with higher presentation white blood cell count (WBC) and microgranular morphology. Early/induction deaths were related to male sex and high presentation WBC. There was a trend for FLT-3 ITD to be associated with non-remission (P = 0.06). For disease-free survival, high WBC was the only significant adverse factor. Male sex, high WBC and FLT-3 ITD were significant adverse factors for overall survival. These findings have important implications on the possible use of FLT-3 inhibitors in the treatment of APL.
引用
收藏
页码:463 / 469
页数:7
相关论文
共 29 条
[1]   Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG) [J].
Asou, N ;
Adachi, K ;
Tamura, J ;
Kanamaru, A ;
Kageyama, S ;
Hiraoka, A ;
Omoto, E ;
Akiyama, H ;
Tsubaki, K ;
Saito, K ;
Kuriyama, K ;
Oh, H ;
Kitano, K ;
Miyawaki, S ;
Takeyama, K ;
Yamada, O ;
Nishikawa, K ;
Takahashi, M ;
Matsuda, S ;
Ohtake, S ;
Ohno, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) :S65-S71
[2]   Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia [J].
Au, WY ;
Kumana, CR ;
Kou, M ;
Mak, R ;
Chan, GCF ;
Lam, CW ;
Kwong, YL .
BLOOD, 2003, 102 (01) :407-408
[3]   Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocytic leukemia and myelodysplastic syndrome [J].
Au, WY ;
Fung, AT ;
Ma, ES ;
Liang, RH ;
Kwong, YL .
CANCER GENETICS AND CYTOGENETICS, 2004, 149 (02) :169-172
[4]   Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia [J].
Au, WY ;
Lie, AKW ;
Chim, CS ;
Liang, R ;
Ma, SK ;
Chan, CH ;
Mak, YK ;
Chen, YT ;
So, CC ;
Yeung, YM ;
Yip, SF ;
Wong, LG ;
Chan, JC ;
Liu, SY ;
Kwong, YL .
ANNALS OF ONCOLOGY, 2003, 14 (05) :752-757
[5]   Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide [J].
Au, WY ;
Chim, CS ;
Lie, AKW ;
Liang, R ;
Kwong, YL .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :130-132
[6]   Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia [J].
Candoni, A ;
Damiani, D ;
Michelutti, A ;
Masolini, P ;
Michieli, M ;
Michelutti, T ;
Geromin, A ;
Fanin, R .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (01) :1-8
[7]   Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance [J].
Chim, CS ;
Wong, SY ;
Kwong, YL .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) :571-578
[8]  
Chim CS, 1996, HEMATOL ONCOL, V14, P147, DOI 10.1002/(SICI)1099-1069(199609)14:3<147::AID-HON582>3.3.CO
[9]  
2-V
[10]   FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors [J].
Gilliland, DG .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2003, 16 (03) :409-417